U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07369102) titled 'Esketamine With or Without Integration Therapy for Treatment-Resistant Depression' on Aug. 22, 2025.
Brief Summary: This study will explore the effects of esketamine (Spravato(R)), an FDA-approved nasal spray, on adults diagnosed with treatment-resistant depression (TRD). All participants will receive esketamine as prescribed by a healthcare professional in a clinical setting.
The purpose of this research is to understand whether adding therapeutic support in the form of preparation and integration sessions - before and after the esketamine doses - can enhance the treatment experience and lead to longer-lasting improvements in mood...